We observed dose-dependent cAMP inhibition after the stimulation of cells with either ligand, demonstrating that CXCR4 and CCR7 are functionally active in advanced human breast cancer cells (Figure 1C). This evidence concerns the gene CCR7 and breast carcinoma.